Please login to the form below

Not currently logged in
Email:
Password:

Prostvac

This page shows the latest Prostvac news and features for those working in and with pharma, biotech and healthcare.

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

CV301 is Bavarian Nordic’s lead cancer vaccine after its much-delayed Prostvac candidate for prostate cancer failed to meet the mark in a phase III trial last year, wreaking havoc ... The setback was also a big disappointment for Bristol-Myers Squibb

Latest news

  • BMS signs $975m deal for Bavarian Nordic cancer vaccine BMS signs $975m deal for Bavarian Nordic cancer vaccine

    Furthermore, Bavarian Nordic could also receive regulatory milestone payments of $110m, up to $495m in sales milestones as well as tiered double-digit royalties on future sales of Prostvac. ... Analysts at Edison Research have predicted that Prostvac

  • Developing therapeutic cancer vaccines Developing therapeutic cancer vaccines

    Viral-vector based vaccines are also in the works. BN ImmunoTherapeutics and the US NCI are developing a viral-vector based vaccine, rilimogene galvacirepvec-rilimogene glafolivec (PROSTVAC), which is in phase

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics